MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$19,347K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Sales of marketable securities
Non-cash interest expense on def...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Outside services
Accrued expenses and other liabi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
9,839
-76,314
-
90,837
Personnel-related expenses
12,776
-52,743
-
66,680
Outside services
17,194
-33,002
-
55,077
Preclinical research and clinical development expenses
2,651
-4,378
-
5,623
Laboratory supplies
722
-8,588
-
9,201
Facility and maintenance expenses
2,934
-8,069
-
11,129
Equipment and office-related expenses
3,089
-10,675
-
13,768
Travel-related expenses
160
-540
-
654
Restructuring and related costs
201
-48,981
-
49,023
Operating expenses
39,727
-166,976
-
211,155
Loss from operations
-29,888
90,662
-
-120,318
Non-cash interest expense related to the sale of future royalties
9,862
-19,194
-
28,661
Revenue
-
-
102,484
-
Interest income
1,723
-6,082
-
7,717
Operating expenses
-
-
260,851
-
Interest and other income (expense), net
-505
2,062
-
-3,073
Loss from operations
-
-
-158,367
-
Non-operating loss
-8,644
15,174
-
-24,017
Loss before provision for income taxes
-38,532
-38,499
-46,844
-144,335
Income tax expense
-
-
-93
-
Income tax benefits (expense)
1
-4
-
-11
Net loss
-38,533
-38,484
-46,762
-56,857
Depreciation and amortization
1,262
1,278
1,624
1,900
Accretion of discount on marketable securities
453
445
531
755
Stock-based compensation
2,010
1,562
1,655
1,552
Non-cash lease expenses
1,240
1,196
1,548
1,495
Impairment charges
-
-
1,694
-
Realized gain on sale of equity securities
-
-
0
-
Unrealized gain on equity securities
-
-
0
0
Non-cash interest expense on deferred royalty obligation
9,862
9,467
9,547
9,670
Other
-97
-109
-111
-157
Accounts receivable
-6,687
8,507
55
-4,077
Prepaid expenses and other assets
-382
1,003
-4,976
-7,953
Accounts payable
-1,685
-2,547
575
2,683
Accrued compensation
831
-9,288
1,394
1,484
Accrued expenses and other liabilities
-12,965
8,403
-79
-3,481
Deferred revenue
-4,176
-1,958
-145
-6,135
Operating lease liability
-2,849
-2,042
-1,987
-1,932
Net cash used in operating activities
-38,290
-42,259
-26,435
-38,189
Purchases of marketable securities
27,848
124,703
4,039
89,938
Maturities of marketable securities
32,026
76,210
2,500
115,516
Sales of marketable securities
15,183
3,240
20,425
14,662
Proceeds from sale of equity securities, net
-
-
0
0
Purchases of equipment and leasehold improvements
0
11
184
251
Net cash used in investing activities
19,361
-45,264
18,702
39,989
Proceeds from sales of common stock, net of issuance costs
-468
103,126
0
0
Payments of debt
-
-
0
0
Proceeds from exercise of common stock options
50
28
3
1
Taxes paid related to net shares settlement of restricted stock units
0
160
67
25
Proceeds from employee stock purchase plan
0
81
0
126
Net cash provided by financing activities
-418
103,075
-64
102
Net decrease in cash, cash equivalents and restricted cash
-19,347
15,552
-7,797
1,902
Cash, cash equivalents and restricted cash at beginning of period
74,540
58,988
66,785
191,162
Cash, cash equivalents and restricted cash at end of period
55,193
74,540
58,988
66,785
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
STRO Cash Flow Sankey Diagram
Sankey diagram visualizing STRO cash flow for the period
Maturities of marketable
securities
$32,026K
(-76.41%↓ Y/Y)
Sales of marketable
securities
$15,183K
(-33.42%↓ Y/Y)
Net cash used in
investing activities
$19,361K
(241.55%↑ Y/Y)
Canceled cashflow
$27,848K
Net decrease in
cash, cash...
-$19,347K
(84.68%↑ Y/Y)
Canceled cashflow
$19,361K
Non-cash interest
expense on deferred...
$9,862K
(-48.07%↓ Y/Y)
Accounts receivable
-$6,687K
(-983.79%↓ Y/Y)
Stock-based compensation
$2,010K
(-81.39%↓ Y/Y)
Depreciation and
amortization
$1,262K
(-66.79%↓ Y/Y)
Non-cash lease expenses
$1,240K
(-56.35%↓ Y/Y)
Accrued compensation
$831K
(172.83%↑ Y/Y)
Prepaid expenses and
other assets
-$382K
(94.05%↑ Y/Y)
Other
-$97K
(67.99%↑ Y/Y)
Proceeds from exercise of
common stock options
$50K
Purchases of marketable
securities
$27,848K
(-83.71%↓ Y/Y)
Net cash used in
operating activities
-$38,290K
(66.00%↑ Y/Y)
Canceled cashflow
$22,371K
Net cash provided by
financing activities
-$418K
(-7066.67%↓ Y/Y)
Canceled cashflow
$50K
Net loss
-$38,533K
(55.95%↑ Y/Y)
Accrued expenses and
other liabilities
-$12,965K
(-282.30%↓ Y/Y)
Deferred revenue
-$4,176K
(93.42%↑ Y/Y)
Operating lease liability
-$2,849K
(19.99%↑ Y/Y)
Accounts payable
-$1,685K
(70.57%↑ Y/Y)
Accretion of discount on
marketable securities
$453K
(-78.92%↓ Y/Y)
Proceeds from sales of
common stock, net of...
-$468K
Loss before
provision for income taxes
-$38,532K
Income tax benefits
(expense)
$1K
Revenue
$9,839K
Interest income
$1,723K
Loss from operations
-$29,888K
Non-operating loss
-$8,644K
Canceled cashflow
$9,839K
Canceled cashflow
$1,723K
Operating expenses
$39,727K
Non-cash interest
expense related to the...
$9,862K
Interest and other income
(expense), net
-$505K
Outside services
$17,194K
Personnel-related expenses
$12,776K
Equipment and
office-related expenses
$3,089K
Facility and maintenance
expenses
$2,934K
Preclinical research and
clinical development...
$2,651K
Laboratory supplies
$722K
Restructuring and related
costs
$201K
Travel-related expenses
$160K
Buy us a coffee